ERBB2 and breast cancer: A meta-analysis of response rates to neoadjuvant therapy showed that the pathologic complete response (pCR) in HER2 + BC was 46% when targeted anti-HER2 therapy (trastuzumab) was used, compared to 25% in the chemotherapy alone group [9].